Jefferies Upgrades Bioage Labs to Buy, Raises Price Target to $62
Benzinga Newsdesk 8 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Jefferies analyst Roger Song upgrades Bioage Labs (NASDAQ:BIOA) from Hold to Buy and raises the price target from $9 to $62.
Jefferies analyst Roger Song upgrades Bioage Labs (NASDAQ:BIOA) from Hold to Buy and raises the price target from $9 to $62.